<DOC>
	<DOCNO>NCT01728688</DOCNO>
	<brief_summary>HBV relate Liver disease common medical problem China . An estimated 7.18 % Chinese ( 93 million ) infect hepatitis B , HBV- relate hepatitis develop liver cirrhosis . Liver transplantation available life save treatment patient end stage liver disease . However , lack donor , surgical complication , rejection , high cost serious problem . In preclinical study investigator demonstrate G-CSF mobilize PBSC patient HBV relate liver cirrhosis could differentiate functional hepatocyte autologous PBSC transplantation significantly improve liver synthetic function . But study need confirm safety efficacy PBSC transplantation . In study , prospective , randomize , parallel clinical study design . The patient HBV-related liver cirrhosis undergo administration human autologous PBSCs via hepatic artery evaluate safety efficacy human autologous PBSCs treatment patient .</brief_summary>
	<brief_title>Safety Efficacy Human Autologous Peripheral Blood Stem Cells Treatment HBV-related Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>1 . Aged 1865 year 2 . HBVrelated liver cirrhosis 3 . ChildPugh score 915 4 . Written consent 1 . Hepatocellular carcinoma malignancy 2 . Severe problem vital organ ( e.g.the heart , renal lung ) 3 . Pregnant lactate woman 4 . Severe bacteria infection 5 . Anticipated difficulty followup observation 6 . Other candidate judge applicable study doctor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>liver cirrhosis</keyword>
	<keyword>stem cell</keyword>
	<keyword>peripheral blood</keyword>
	<keyword>autologous</keyword>
	<keyword>HBV</keyword>
	<keyword>end stage liver disease</keyword>
</DOC>